June 27, 2024

Second Phase 3 trial shows benefit of xanomeline‐trospium in schizophrenia

Key Points

Key points are not available for this paper at this time.

Abstract

A 5‐week trial has found that the combination of the muscarinic receptor agonist xanomeline and the peripheral muscarinic antagonist trospium significantly reduced symptoms of schizophrenia in adults. The xanomeline‐trospium combination was well‐tolerated, with no significant difference from placebo in extrapyramidal symptoms or weight gain.

Connected Papers

Building similarity graph...

Analyzing shared references across papers

Discussion

Cite this study

A Thu, study studied this question.

synapsesocial.com/papers/68e63117b6db6435875c2e15 — DOI: https://doi.org/10.1002/pu.31190

Also consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

Xanomeline‐trospium combination shows strong results in schizophrenia trial· 2024
Trial shows safety of switch to xanomeline‐trospium combination in stable patients· 2026
Efficacy and Safety of Xanomeline-Trospium Chloride in Schizophrenia· 2024 · 156 citations
Long-Term Safety and Efficacy of Xanomeline and Trospium Chloride in Schizophrenia: A 52-Week Open-Label Extension Trial· 2026 · 5 citations
Analytical Methods for Xanomeline and Trospium Chloride: A Review and Future Outlook· 2025 · 1 citations

Second Phase 3 trial shows benefit of xanomeline‐trospium in schizophrenia

Key Points

Abstract

Citation Network

Connected Papers

Discussion

Cite this study

Also consider

Journals

Actions

References and Citations

Citation Network

Connected Papers

Discussion

Also consider